Navigation Links
Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance

CARY, N.C., April 26, 2011 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), today announced the appointment of James "Jay" Dixon to Senior Vice President, Quality and Compliance. Dixon has spent more than 25 years in the pharmaceutical, biotechnology and CRO industries, and will bring his extensive experience to support Cetero's objective of maintaining its market leadership position.

(Photo: )

At Cetero, Dixon will lead the Quality and Compliance team, ensuring that Cetero's unwavering commitment to quality provides its clients with the most dependable and accurate results.

"We are thrilled to have someone of Jay's caliber joining the Cetero team," said CEO Troy W. McCall, Ph.D. "Cetero considers quality and compliance to be the utmost priority. Jay's qualifications and background will undoubtedly help raise Cetero's benchmark for quality to an unprecedented new level."

Dixon's career has focused on clinical (GCP), preclinical (GLP), manufacturing (GMP) quality, medical operations and analytical chemistry. Dixon most recently led the quality and compliance efforts for MedImmune, LLC, as Vice President of GxP Quality Compliance. Prior to that, he was at Covance Central Laboratory Services as Vice President of Global Quality Assurance and Business Process Improvement – Six Sigma.

"Quality, safety and consistency are more important than ever in our industry," Dixon said. "I am committed to building upon Cetero's reputation as the leader in early-stage clinical research and to further improving on our record of high-quality performance and reliability."

Prior to his work at Covance, Dixon also held quality-focused leadership positions at Abbott Laboratories, Inc., Triangle Pharmaceuticals (now Gilead Sciences), PAREXEL International Corporation, ClinTrials Research, Inc., Glaxo, Inc. and Glaxo Wellcome, Inc. Dixon holds a bachelor's degree in biology from Campbell University in North Carolina. He is a member of the Board of Directors of Frederick Memorial Healthcare System in Frederick, Maryland, the Drug Information Association (DIA) and the Society of Quality Assurance (SQA).

About Cetero Research

Cetero Research, the leading early-phase contract research organization (CRO), has conducted more than 20,000 clinical pharmacology studies, more than any other CRO. With facilities across North America, Cetero offers flexible, high-quality clinical development services in a range of therapeutic areas, including asthma and allergy, dermatology and diabetes, as well as bioanalytical services to support clinical, preclinical drug and biomarker analysis for small and large molecules. It uses innovative approaches, such as the Accelerated Proof-of-Concept study design to provide key decision-making data earlier in the development process. A pioneer in the pharmaceutical and biotechnology industries, Cetero prioritizes ensuring the safety of its patient and normal healthy study participants, reporting high-quality, reliable data and providing on-time results. For more information, visit or call 877.7CETERO

SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Leads Industry in Human Allergy Models
2. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
3. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
4. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
5. Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
10. Video: New Research Discovers Independent Brain Networks Control Human Walking
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):